Selinexor (KPT-330) Mechanism of Action: XPO1 Inhibition in Plasma Cell Research

Selinexor (KPT-330) MOA:Targeting XPO1/Nuclear Export Pathway for Multiple Myeloma

🎯 check Selinexor (KPT-330) product page

Selinexor (KPT-330) is a potent, selective, and orally bioavailable XPO1 inhibitor. It affects p53, PI3K/AKT, and NF-κB signaling pathways. By blocking the nuclear export of tumor suppressor proteins, it effectively inhibits cancer cell proliferation and induces apoptosis.

Primary Applications and Mechanism of Action